Destiny Pharma Ltd. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 28
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: D8BECB45DC5EN
Leaflet:

Download PDF Leaflet

Destiny Pharma Ltd. - Product Pipeline Review - Q4 2010
Destiny Pharma Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Destiny Pharma Ltd. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Destiny Pharma Ltd. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Destiny Pharma Ltd. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Destiny Pharma Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Destiny Pharma Ltd.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Destiny Pharma Ltd.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Destiny Pharma Ltd. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Destiny Pharma Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Destiny Pharma Ltd..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Destiny Pharma Ltd. and identify potential opportunities in those areas.
Destiny Pharma Ltd. Snapshot
Destiny Pharma Ltd. Overview
Key Information
Key Facts
Destiny Pharma Ltd. – Research and Development Overview
Key Therapeutic Areas
Destiny Pharma Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Destiny Pharma Ltd. – Pipeline Products Glance
Destiny Pharma Ltd. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Destiny Pharma Ltd.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Destiny Pharma Ltd. – Drug Profiles
XF 73
  Product Description
  Mechanism of Action
  R&D Progress
DPD-207
  Product Description
  Mechanism of Action
  R&D Progress
XF 73
  Product Description
  Mechanism of Action
  R&D Progress
XF-42
  Product Description
  Mechanism of Action
  R&D Progress
Destiny Pharma Ltd. – Pipeline Analysis
Destiny Pharma Ltd. – Pipeline Products by Therapeutic Class
Destiny Pharma Ltd. Pipeline Products By Target
Destiny Pharma Ltd. – Pipeline Products by Route of Administration
Destiny Pharma Ltd. – Pipeline Products by Molecule Type
Destiny Pharma Ltd. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 01, 2008: Destiny Pharma Presents At The Joint 48th Annual Interscience Conference On Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases of America (IDSA) 46th Annual Meeting In Washington, USA
Financial Deals Landscape
Destiny Pharma Ltd., Deals Summary, 2004 to 2010
Destiny Pharma Ltd. Detailed Deal Summary
Venture Financing
Destiny Pharma Secures $7 Million In Venture Financing Round
Destiny Pharma Secures $5.5 Million In Venture Financing Round
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 28

LIST OF TABLES

Destiny Pharma Ltd. – Pipeline by Therapy Area and Indication, 2010
Destiny Pharma Ltd. – Pipeline by Stage of Development, 2010
Destiny Pharma Ltd. – Monotherapy Products in Pipeline, 2010
Destiny Pharma Ltd. - Phase I, 2010
Destiny Pharma Ltd. - Pipeline By Therapeutic Class, 2010
Destiny Pharma Ltd. - Pipeline By Target, 2010
Destiny Pharma Ltd. – Pipeline By Route of Administration, 2010
Destiny Pharma Ltd. – Pipeline By Molecule Type, 2010
Destiny Pharma Ltd., Deals Summary, 2004 to 2010
Destiny Pharma Secures $7 Million In Venture Financing Round
Destiny Pharma Secures $5.5 Million In Venture Financing Round 25

LIST OF FIGURES

Destiny Pharma Ltd. – Pipeline by Therapy Area and Indication, 2010
Destiny Pharma Ltd. – Pipeline by Stage of Development, 2010
Destiny Pharma Ltd. – Monotherapy Products in Pipeline, 2010
Destiny Pharma Ltd. – Pipeline By Therapeutic Class, 2010 17
Antares Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 40 pages
Dey Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 40 pages
Endotis Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Dec, 2010 · 27 pages
ERYtech Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Dec, 2010 · 36 pages

Ask Your Question

Destiny Pharma Ltd. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: